Skip to main content
Figure 2 | BMC Pulmonary Medicine

Figure 2

From: IL-27 alleviates the bleomycin-induced pulmonary fibrosis by regulating the Th17 cell differentiation

Figure 2

Exogenous IL-27 treatment can suppress BLM-induced pulmonary fibrosis.A. Hematoxylin and eosin (HE) staining (100x) and Masson’s trichrome staining (100x) depicting the effects of exogenous IL-27 application on lung histological changes at days 7 and 28 in various treated mice. B. The alveolitis and fibrosis scores for the lungs of mice in the different groups at days 7 and 28. Values are means ± SEM (n = 5). C, D, E. Real-time PCR and Western blot analysis for COL1 and COL3, respectively, in the different groups. CT values for the real-time PCR were normalized by 2-∆∆ct. Western band intensities were measured using Image J software. For each group, n = 3. F. The lung hydroxyproline content at days 7 and 28 for mice in the various treatment groups. Hydroxyproline content was measured using an ELISA, n = 5. G. Survival rate of mice with BLM-induced pulmonary fibrosis. The percentage of survival over time is presented, n = 5. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01. A: control, B: BLM group, C: BLM + IL-27 group, D: BLM + IL-27 antibody group.

Back to article page